Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
FDA issued guidance on compounding animal drugs from bulk drug substances under CGMP in federally-registered facilities, clarifying requirements for outsourcing facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding outsourcing facilities (503B) that compound animal drugs from bulk drug substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline stated; guidance is effective immediately.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance outlining CGMP expectations for compounding animal drugs from bulk drug substances in federally-registered facilities.
Who it affects
Compounding outsourcing facilities (503B) that compound animal drugs from bulk drug substances.
What you must do
Review the guidance and assess current compounding practices for compliance with CGMP requirements.
Deadline
No specific deadline stated; guidance is effective immediately.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA to require diversity plan for clinical trials - nature.com
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments